Streetbeat News

Stock Prices

GS

JP Morgan analyst Kian Abouhossein maintains an Overweight rating on Goldman Sachs Group (NYSE:GS) and increases the price target from $398 to $421.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:25 pm

HPE

Hewlett Packard Enterprise (HPE) shares are trading lower after reports surfaced about the company being close to finalizing an acquisition deal with Juniper Networks.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:24 pm

BTCUSD

El Salvador's sovereign bonds, particularly the one due in June 2035, have surged over 200% following the country's Bitcoin investments turning profitable. Bitcoin's value doubled, coinciding with the bond rally and the anticipated approval of a Bitcoin ETF. El Salvador's economy grew by 3.6% in Q3 2023, and its Bitcoin portfolio has seen a 10.2% increase in profits. Despite IMF warnings about the risks of Bitcoin as legal tender and Bitcoin-backed bonds, El Salvador's financial strategy appears successful for now.

Portfolio Pulse from Piero Cingari

January 09, 2024 | 2:24 pm

KYMR

Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its 2024 objectives, focusing on advancing its immunology and oncology programs. The company expects to complete enrollment for Phase 2 studies of KT-474 in Q4 2024, with topline data due in H1 2025. Phase 1 trials for KT-621 and KT-294 are set for H2 2024 and H1 2025, respectively. KT-333 and KT-253 are expected to complete Phase 1a studies in 2024. Kymera is well-capitalized with over $745M in cash, providing a runway into H1 2027. The company will present at the J.P. Morgan Annual Healthcare Conference on January 9, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:19 pm

EFTR

EFFECTOR Therapeutics' stock price is trading lower following the announcement of a 1-for-25 reverse stock split. This corporate action often indicates a company's attempt to boost its share price to meet exchange listing requirements or to attract more institutional investors. However, it can also be perceived negatively by the market as it may signal underlying issues with the company's fundamentals or a lack of positive growth prospects.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:16 pm

AAPL

AMD

BA

BTCUSD

CORN

HOOD

MARA

NVDA

QQQ

TSLA

Swaggy Stocks has listed the top 10 trending stocks on WallStreetBets as of January 9, 2024. The stocks include NVDA, BA, AAPL, BTCUSD, QQQ, CORN, TSLA, HOOD, AMD, and MARA.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:15 pm

MUFG

Mitsubishi UFJ Financial Group Inc. (NYSE:MUFG) stock is currently trading at $8.79, down 1.12% in the current session, but up 1.03% over the past month and 28.32% over the past year. The company's P/E ratio of 8.64 is lower than the Banks industry average of 14.58, which could suggest the stock is undervalued or expected to perform worse than its peers. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative analysis for a comprehensive investment decision.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 2:15 pm

ACRX

AcelRx Pharmaceuticals has announced a rebranding initiative, including a name change to Talphera. The company will start trading on Nasdaq under the new ticker symbol 'TLPH' starting January 10, 2024. This rebranding signifies a new phase for the company as it collaborates with the medical community to develop innovative solutions for medically supervised settings.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:11 pm

PFE

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $45 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:10 pm

NFLX

Netflix Inc (NASDAQ:NFLX) stock is trading lower after Citigroup downgraded the company from a Buy to a Neutral rating with a price target of $500. BMO Capital initiated coverage with an Outperform rating and a price target of $566, while Goldman Sachs maintained a Neutral rating and raised their price target from $400 to $500. The average analyst price target is $436.03. Netflix is expected to report Q4 earnings of $2.21 per share on revenue of $8.705 billion. The stock was down 1.76% at $476.50.

Portfolio Pulse from Adam Eckert

January 09, 2024 | 2:10 pm